针对HER2和uPAR基因靶向治疗乳腺癌的研究
摘要
乳腺癌为女性最常见的恶性肿瘤之一,全世界每年约有120万人新患乳腺癌,约50万人死于乳腺癌。近年来,在我国城市地区的乳腺癌发病率和死亡率也呈明显上升趋势。乳腺癌是一种全身性疾病,术后复发转移率高,即使处于癌症早期,也有潜在转移的可能性。当乳腺癌发生转移时,目前无特效治疗方法,以死亡为转归。因此,探讨肿瘤发病机制,寻找新的治疗靶点,及可用于诊断和预后判断的生物标志物,是当今肿瘤学研究的重要内容。
HER2/neu是一种重要的原癌基因,其表达产物属于EGF受体家庭2号成员。该家族共有4名成员,分别为HER1、HER2、HER3和HER4,各成员具有相似的分子结构和功能。EGF受体家族成员通过配体形成同源或异源二聚体,活化胞内酪氨酸激酶,从而激活信号转导通路。EGFR家族介导的胞内信号途径主要有4条,调控细胞的增殖、分化、迁移、粘附、存活及凋亡等
uPAR为尿激酶纤溶酶原受体,是一种高度糖基化膜蛋白,由糖基化磷脂酰肌醇( GPI )锚定在细胞膜表面。uPAR在多种细胞和组织中表达,包括肿瘤组织及其细胞系。在肿瘤细胞中,uPAR的过表达预示肿瘤的恶性程度高和不良预后。uPAR是一个多功能的细胞表面分子,不但,能在细胞表面富集uPA,激活纤溶酶原系统,引起细胞外基质(ECM)蛋白水解,促进细胞转移与侵袭,而且,还能与细胞表面其它分子,如整合素和甲酰甲硫氨酸受体及玻璃粘连蛋白等相互作用,调控细胞粘附、增殖、凋亡、以及肿瘤休眠过等过程。
Herceptin是一种针对HER2的人源化单克隆抗体,能够特异性识别HER2蛋白的胞外功能区,抑制其介导的信号传导通路。Herceptin是美国FDA批准的第一种分子靶向药物,为乳腺癌尤其是HER2过表达乳腺癌的临床治疗带来了新的突破。临床研究证实,Herceptin主要应用于HER2基因过表达的乳腺癌患者群。Herceptin单独使用对HER2基因扩增的患者有效率约25%,与化疗药物联用有效率为50%左右。患者使用Herceptin治疗后,平均能够延长1年左右的生存期。但是,对HER2基因低表达乳腺癌患者群,疗效较差。
先前的研究显示,HER2和uPAR在表达上存在相互影响作用。所以,本研究利用RNA干扰技术初步探讨HER2与uPAR在表达上是否存在相互调控关系;并在体外和体内水平进一步研究了以HER2和uPAR为靶标,对乳腺癌协同治疗。
(1)以人HER2和uPAR基因为靶基因,设计和构建了分别单独针对HER2与uPAR基因的RNAi表达载体(pHER2和puPAR)和同时针对HER2和uPAR基因的RNAi表达载体(pHu),将其转染乳腺癌细胞,并用real time PCR和western blotting检测其抑制靶基因表达的效果。结果显示,我们成功构建的RNAi表达载体,并证实其在乳腺癌细胞中能高效抑制靶基因的表达。
(2)将重组RNAi表达载体转染乳腺癌细胞,用real time PCR、western blotting和IF同时检测每个转染组中两种靶基因的表达情况,从而,探讨HER2与uPAR在表达上的相互关系。结果显示,将重组质粒pHER2转染细胞时,不但能高效抑制HER2表达,同时能够部分的抑制uPAR的表达;同样,将puPAR转染细胞时,不但能高效抑制uPAR表达,同时能够部分的抑制HER2的表达;将pHu转染乳腺癌细胞,与pHER2和puPAR相比,对HER2或uPAR基因的表达抑制作用更为显著。
(3)利用RNA干扰技术单独或同时抑制HER2和uPAR基因的表达,并检测其对乳腺癌细胞增殖、凋亡、周期、侵袭力以及MAPK信号调控通路活化的影响。结果显示,单独或同时敲降HER2和uPAR基因在乳腺癌细胞中的表达时,都能抑制细胞的增殖、促进细胞的凋亡、降低细胞的侵袭力、抑制MAPK信号通路的活化以及使乳腺癌细胞G0/G1发生阻滞。同时敲降HER2和uPAR基因表达与单独敲降HER2或uPAR基因表达相比,其效果更为显著。
(4)将Herceptin和puPAR单独或联合用药,在细胞水平探讨其对乳腺癌细胞增殖、凋亡、周期、侵袭力以及MAPK信号调控通路活化的影响。结果显示,将Herceptin和puPAR单独或联合处理乳腺癌细胞时,都能抑制细胞的增殖、促进细胞的凋亡、降低细胞的侵袭力、抑制MAPK信号通路的活化以及使乳腺癌细胞G0/G1发生阻滞。联合用药与单独用药相比,其效果更为显著。
(5)将Herceptin和puPAR单独或联合用药,在体内水平探讨其对荷瘤鼠的治疗作用。动物试验表明,Herceptin对HER2低表达、uPAR高表达型肿瘤治疗作用不明显,puPAR对肿瘤的生长有很好的抑制作用。当Herceptin与puPAR联合用药时,对荷瘤鼠有更为显著的治疗作用。
综上所述,本研究初步证实HER2和uPAR在表达上确实存在调控关系。同时敲降HER2和uPAR基因表达与单独敲降HER2与uPAR表达相比,对抑制细胞的增殖、促进细胞的凋亡和降低细胞的侵袭力等具有叠加或协同作用。体外和体内试验证实,敲降uPAR基因能够提高乳腺癌细胞对Herceptin治疗的敏感性。
Breast cancer is one of the most frequent malignant tumors in female. There are about 120 million women suffering from breast cancer, about 50 million women die of this disease all of the world each year. In recent years, the morbidity of breast cancer was increased sharply in the cities of China. Breast cancer is a systemic disease, the recurrence and metastasis rates are very high after surgical operation, and even the primary tumors have the possibility of metastasis. There are no effective therapy methods for breast cancer after the tumor metastasis to a distant organ. Therefore, to study the pathogenesis of cancer, explore the diagnostic and prognostic biomarkers, and find new therapeutic targets is an important oncology research content in today.
HER2 is an important oncogene, its expression product belongs to the epidermal growth factor receptor (EGFR) family. The EGFR family includes four members of HER1, HER2, HER3 and HER4. All of the members have similar moecule structures and functions. EGFR family members binding with ligands to form homo-dimers or hetero-dimers activate intracellular tyrosine kinase, which further activate cysto-signal transduction pathway. EGFR family mediate four mainly cysto-signal transduction pathways, which regulate diverse biological responses, such as proliferation, differentiation, cell motility, and survival.
Urokinase-type plasminogen activator receptor (uPAR) is highly glycosylated, extracellular protein, be attached to the cell surface by a GPI anchor. CD87 is a broadly expressed protein, including expression in tumor tissue and cell lines. In tumor cells, uPAR over-expression indicates the worsening of malignant tumors and poor prognosis. uPAR is a multifunctional surface molecular and has the principle function of retaining and concentrating uPA at the cell surface for conversion of plasminogen to plasmin, which exerts its primary role of pericellular proteolysis by activating several metalloproteinases. This process is critical for chemotaxis and cell migration. uPAR can interact with some cell surface factors (integrin formyl Methionine receptor and Vitronectin) and play an important role in cell adhesion, proliferation, apoptosis, and tumor dormancy.
Herceptin is a recombinant humanized monoclonal antibody against the HER2 protein that can specifically recognize and bind to the extracellular domain of HER2 molecule. The mechanisms of the action of this antibody involve inhibition of signal transduction. As the first molecular drug, which was approved by FDA, Herceptin bring a new break-through for breast cancer clinical treatment, especially for HER2/neu positive breast cancer patients. Clinical study confirmed that Herceptin mainly was used to treat HER2 over-expression breast cancer patients. When Herceptin was used to cure HER2 gene amplification patients alone, the efficiency is about 25%; when Herceptin combined with chemotherapy, the efficiency is about 50%. After treatment of Herceptin, the average survival period of patients can be extended one year. However, for HER2 low expression breast cancer group, Herceptin has a poor treatment outcome.
Previous studies have shown HER2 and uPAR expression exist mutually influence. So, we used RNAi technology to study if HER2 and uPAR could regulate protein expresson mutually; and explore synergistic therapy for breast cancer targeting to HER2 and uPAR.
(1) With human HER2 and uPAR gene as a target gene, design and construct the specificity RNA interference plasmid vectors pHER2, puPAR and pHu. pHER2 and puPAR target to HER2 and uPAR respectively; Among them, pHu target both HER2 and uPAR. Then, use real time PCR and western blotting to detect the effect of inhibition target genes expression. The results displayed that we successfully constructed four RNAi plasmids. pHER2 and puPAR can inhibite HER2 or uPAR gene expression respectively in breast cancer cells; and pHu can inhibit both HER2 and uPAR genes expression. Compare pHu with pHER2 or puPAR, pHu has a high efficiency of inhibition HER2 or uPAR gene expression in breast cancer cells.
(2) Transfect pHER2, puPAR and pHu to breast cancer cells, and use real time PCR, western blotting, and IF to detect HER2 and uPAR genes expression levels in each transfection group. The results showed that transfected pHER2 to breast cancer cells not only strongly inhibited HER2 expression, but also partly inhibited uPAR expression. Likewise, when puPAR was transfected to breast cancer cells, not only strongly inhibited uPAR expression, but also partly inhibited HER2 expression. Compare pHu with pHER2 or puPAR, pHu has prominence efficiency in inhibition both HER2 and uPAR genes expression.
(3) pHER2, puPAR and pHu was transfected to breast cancer cells, then detected and analyzed breast cancer cells proliferation, apoptosis, cycles, invasiveness, and regulation of MAPK signaling pathway activation. The results displayed that pHER2, puPAR and pHu was transfected to breast cancer cells respectively, which all could inhibit cells proliferation, promote apoptosis, reduce cell invasiveness, inhibit activation of MAPK signaling pathway and make cells G0/G1 arrest. But pHu has a stronger efficiency than pHER2 or puPAR.
(4) Breast cancer cells were treated with Herceptin, puPAR or both Herceptin and puPAR respectively. Then, breast cancer cells proliferation, apoptosis, cycles, invasiveness, and regulation of MAPK signaling pathway activation were detected and analyzed. The results showed that breast cancer cells were treated with Herceptin, puPAR or both Herceptin and puPAR respectively, which all could inhibit cells proliferation, promote apoptosis, reduce cell invasiveness, inhibit activation of MAPK signaling pathway and make cells G0/G1 arrest. But when breast cancer cells were treated with both Herceptin and puPAR has a stronger efficiency than Herceptin or puPAR alone.
(5) Tumor-bearing mice were treated with Herceptin, puPAR or both Herceptin and puPAR, respectively. Then the Anti-tumor effect was detected and analyzed. The results of animal experiments showed that for HER2 low expression breast cancer cell line, puPAR has a strong effect to inhibit tumor growth, but Herceptin just has a low effect. When tumor-bearing mice were treated with both Herceptin and puPAR have a more significant addition or synergistic therapeutic effects than tumor-bearing mice were treated with Herceptin or puPAR alone.
In conclusion: HER2 could regulate uPAR expression and uPAR also could regulate HER2 gene expression; Simultaneity inhibition HER2 and uPAR expression has a more significant addition or synergistic effects than inhibition HER2 or uPAR alone on inhibition cells proliferation, promotion apoptosis, decrease cell invasiveness, inhibition activation of MAPK signaling pathway and making cells G0/G1 arrest; Knocking down uPAR gene can increase the sensitivity of breast cancer cells to Herceptin.
HER2/neu是一种重要的原癌基因,其表达产物属于EGF受体家庭2号成员。该家族共有4名成员,分别为HER1、HER2、HER3和HER4,各成员具有相似的分子结构和功能。EGF受体家族成员通过配体形成同源或异源二聚体,活化胞内酪氨酸激酶,从而激活信号转导通路。EGFR家族介导的胞内信号途径主要有4条,调控细胞的增殖、分化、迁移、粘附、存活及凋亡等
uPAR为尿激酶纤溶酶原受体,是一种高度糖基化膜蛋白,由糖基化磷脂酰肌醇( GPI )锚定在细胞膜表面。uPAR在多种细胞和组织中表达,包括肿瘤组织及其细胞系。在肿瘤细胞中,uPAR的过表达预示肿瘤的恶性程度高和不良预后。uPAR是一个多功能的细胞表面分子,不但,能在细胞表面富集uPA,激活纤溶酶原系统,引起细胞外基质(ECM)蛋白水解,促进细胞转移与侵袭,而且,还能与细胞表面其它分子,如整合素和甲酰甲硫氨酸受体及玻璃粘连蛋白等相互作用,调控细胞粘附、增殖、凋亡、以及肿瘤休眠过等过程。
Herceptin是一种针对HER2的人源化单克隆抗体,能够特异性识别HER2蛋白的胞外功能区,抑制其介导的信号传导通路。Herceptin是美国FDA批准的第一种分子靶向药物,为乳腺癌尤其是HER2过表达乳腺癌的临床治疗带来了新的突破。临床研究证实,Herceptin主要应用于HER2基因过表达的乳腺癌患者群。Herceptin单独使用对HER2基因扩增的患者有效率约25%,与化疗药物联用有效率为50%左右。患者使用Herceptin治疗后,平均能够延长1年左右的生存期。但是,对HER2基因低表达乳腺癌患者群,疗效较差。
先前的研究显示,HER2和uPAR在表达上存在相互影响作用。所以,本研究利用RNA干扰技术初步探讨HER2与uPAR在表达上是否存在相互调控关系;并在体外和体内水平进一步研究了以HER2和uPAR为靶标,对乳腺癌协同治疗。
(1)以人HER2和uPAR基因为靶基因,设计和构建了分别单独针对HER2与uPAR基因的RNAi表达载体(pHER2和puPAR)和同时针对HER2和uPAR基因的RNAi表达载体(pHu),将其转染乳腺癌细胞,并用real time PCR和western blotting检测其抑制靶基因表达的效果。结果显示,我们成功构建的RNAi表达载体,并证实其在乳腺癌细胞中能高效抑制靶基因的表达。
(2)将重组RNAi表达载体转染乳腺癌细胞,用real time PCR、western blotting和IF同时检测每个转染组中两种靶基因的表达情况,从而,探讨HER2与uPAR在表达上的相互关系。结果显示,将重组质粒pHER2转染细胞时,不但能高效抑制HER2表达,同时能够部分的抑制uPAR的表达;同样,将puPAR转染细胞时,不但能高效抑制uPAR表达,同时能够部分的抑制HER2的表达;将pHu转染乳腺癌细胞,与pHER2和puPAR相比,对HER2或uPAR基因的表达抑制作用更为显著。
(3)利用RNA干扰技术单独或同时抑制HER2和uPAR基因的表达,并检测其对乳腺癌细胞增殖、凋亡、周期、侵袭力以及MAPK信号调控通路活化的影响。结果显示,单独或同时敲降HER2和uPAR基因在乳腺癌细胞中的表达时,都能抑制细胞的增殖、促进细胞的凋亡、降低细胞的侵袭力、抑制MAPK信号通路的活化以及使乳腺癌细胞G0/G1发生阻滞。同时敲降HER2和uPAR基因表达与单独敲降HER2或uPAR基因表达相比,其效果更为显著。
(4)将Herceptin和puPAR单独或联合用药,在细胞水平探讨其对乳腺癌细胞增殖、凋亡、周期、侵袭力以及MAPK信号调控通路活化的影响。结果显示,将Herceptin和puPAR单独或联合处理乳腺癌细胞时,都能抑制细胞的增殖、促进细胞的凋亡、降低细胞的侵袭力、抑制MAPK信号通路的活化以及使乳腺癌细胞G0/G1发生阻滞。联合用药与单独用药相比,其效果更为显著。
(5)将Herceptin和puPAR单独或联合用药,在体内水平探讨其对荷瘤鼠的治疗作用。动物试验表明,Herceptin对HER2低表达、uPAR高表达型肿瘤治疗作用不明显,puPAR对肿瘤的生长有很好的抑制作用。当Herceptin与puPAR联合用药时,对荷瘤鼠有更为显著的治疗作用。
综上所述,本研究初步证实HER2和uPAR在表达上确实存在调控关系。同时敲降HER2和uPAR基因表达与单独敲降HER2与uPAR表达相比,对抑制细胞的增殖、促进细胞的凋亡和降低细胞的侵袭力等具有叠加或协同作用。体外和体内试验证实,敲降uPAR基因能够提高乳腺癌细胞对Herceptin治疗的敏感性。
Breast cancer is one of the most frequent malignant tumors in female. There are about 120 million women suffering from breast cancer, about 50 million women die of this disease all of the world each year. In recent years, the morbidity of breast cancer was increased sharply in the cities of China. Breast cancer is a systemic disease, the recurrence and metastasis rates are very high after surgical operation, and even the primary tumors have the possibility of metastasis. There are no effective therapy methods for breast cancer after the tumor metastasis to a distant organ. Therefore, to study the pathogenesis of cancer, explore the diagnostic and prognostic biomarkers, and find new therapeutic targets is an important oncology research content in today.
HER2 is an important oncogene, its expression product belongs to the epidermal growth factor receptor (EGFR) family. The EGFR family includes four members of HER1, HER2, HER3 and HER4. All of the members have similar moecule structures and functions. EGFR family members binding with ligands to form homo-dimers or hetero-dimers activate intracellular tyrosine kinase, which further activate cysto-signal transduction pathway. EGFR family mediate four mainly cysto-signal transduction pathways, which regulate diverse biological responses, such as proliferation, differentiation, cell motility, and survival.
Urokinase-type plasminogen activator receptor (uPAR) is highly glycosylated, extracellular protein, be attached to the cell surface by a GPI anchor. CD87 is a broadly expressed protein, including expression in tumor tissue and cell lines. In tumor cells, uPAR over-expression indicates the worsening of malignant tumors and poor prognosis. uPAR is a multifunctional surface molecular and has the principle function of retaining and concentrating uPA at the cell surface for conversion of plasminogen to plasmin, which exerts its primary role of pericellular proteolysis by activating several metalloproteinases. This process is critical for chemotaxis and cell migration. uPAR can interact with some cell surface factors (integrin formyl Methionine receptor and Vitronectin) and play an important role in cell adhesion, proliferation, apoptosis, and tumor dormancy.
Herceptin is a recombinant humanized monoclonal antibody against the HER2 protein that can specifically recognize and bind to the extracellular domain of HER2 molecule. The mechanisms of the action of this antibody involve inhibition of signal transduction. As the first molecular drug, which was approved by FDA, Herceptin bring a new break-through for breast cancer clinical treatment, especially for HER2/neu positive breast cancer patients. Clinical study confirmed that Herceptin mainly was used to treat HER2 over-expression breast cancer patients. When Herceptin was used to cure HER2 gene amplification patients alone, the efficiency is about 25%; when Herceptin combined with chemotherapy, the efficiency is about 50%. After treatment of Herceptin, the average survival period of patients can be extended one year. However, for HER2 low expression breast cancer group, Herceptin has a poor treatment outcome.
Previous studies have shown HER2 and uPAR expression exist mutually influence. So, we used RNAi technology to study if HER2 and uPAR could regulate protein expresson mutually; and explore synergistic therapy for breast cancer targeting to HER2 and uPAR.
(1) With human HER2 and uPAR gene as a target gene, design and construct the specificity RNA interference plasmid vectors pHER2, puPAR and pHu. pHER2 and puPAR target to HER2 and uPAR respectively; Among them, pHu target both HER2 and uPAR. Then, use real time PCR and western blotting to detect the effect of inhibition target genes expression. The results displayed that we successfully constructed four RNAi plasmids. pHER2 and puPAR can inhibite HER2 or uPAR gene expression respectively in breast cancer cells; and pHu can inhibit both HER2 and uPAR genes expression. Compare pHu with pHER2 or puPAR, pHu has a high efficiency of inhibition HER2 or uPAR gene expression in breast cancer cells.
(2) Transfect pHER2, puPAR and pHu to breast cancer cells, and use real time PCR, western blotting, and IF to detect HER2 and uPAR genes expression levels in each transfection group. The results showed that transfected pHER2 to breast cancer cells not only strongly inhibited HER2 expression, but also partly inhibited uPAR expression. Likewise, when puPAR was transfected to breast cancer cells, not only strongly inhibited uPAR expression, but also partly inhibited HER2 expression. Compare pHu with pHER2 or puPAR, pHu has prominence efficiency in inhibition both HER2 and uPAR genes expression.
(3) pHER2, puPAR and pHu was transfected to breast cancer cells, then detected and analyzed breast cancer cells proliferation, apoptosis, cycles, invasiveness, and regulation of MAPK signaling pathway activation. The results displayed that pHER2, puPAR and pHu was transfected to breast cancer cells respectively, which all could inhibit cells proliferation, promote apoptosis, reduce cell invasiveness, inhibit activation of MAPK signaling pathway and make cells G0/G1 arrest. But pHu has a stronger efficiency than pHER2 or puPAR.
(4) Breast cancer cells were treated with Herceptin, puPAR or both Herceptin and puPAR respectively. Then, breast cancer cells proliferation, apoptosis, cycles, invasiveness, and regulation of MAPK signaling pathway activation were detected and analyzed. The results showed that breast cancer cells were treated with Herceptin, puPAR or both Herceptin and puPAR respectively, which all could inhibit cells proliferation, promote apoptosis, reduce cell invasiveness, inhibit activation of MAPK signaling pathway and make cells G0/G1 arrest. But when breast cancer cells were treated with both Herceptin and puPAR has a stronger efficiency than Herceptin or puPAR alone.
(5) Tumor-bearing mice were treated with Herceptin, puPAR or both Herceptin and puPAR, respectively. Then the Anti-tumor effect was detected and analyzed. The results of animal experiments showed that for HER2 low expression breast cancer cell line, puPAR has a strong effect to inhibit tumor growth, but Herceptin just has a low effect. When tumor-bearing mice were treated with both Herceptin and puPAR have a more significant addition or synergistic therapeutic effects than tumor-bearing mice were treated with Herceptin or puPAR alone.
In conclusion: HER2 could regulate uPAR expression and uPAR also could regulate HER2 gene expression; Simultaneity inhibition HER2 and uPAR expression has a more significant addition or synergistic effects than inhibition HER2 or uPAR alone on inhibition cells proliferation, promotion apoptosis, decrease cell invasiveness, inhibition activation of MAPK signaling pathway and making cells G0/G1 arrest; Knocking down uPAR gene can increase the sensitivity of breast cancer cells to Herceptin.
引文
Aguirre Ghiso J A, Kovalski K, Ossowski L. 1999. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol, 147(1):89~104
Allgayer H, Babic R, Gruetzner K U, Tarabichi A, Schildberg F W, Heiss M M. 2000. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol, 18(11): 2201~9
Amin D N, Perkins A S, Stern D F. 2004. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene, 23(7): 1428~38
Andreasen P A, Egelund R, Petersen H H. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci, 57 (1): 25~40
Anichini E, Zamperini A, Chevanne M, Caldini R, Pucci M, Fibbi G., Del Rosso M. 1997. Interaction of urokinase-type plasminogen activator with its receptor rapidly induces activation of glucose transporters. Biochemistry, 36(11): 3076~83
Azria D, Larbouret C, Robert B, Culine S, Ychou M, Verrelle P, Dubois JB, Pèlegrin A. 2003. Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials. Bull Cancer, 90 Spec No: S202~12
Baker E A, Bergin FG, Leaper D J. 2000. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol, 53: 307~12
Baselga J, Albanell J, Molina M A, Arribas J. 2001. Mechanism of action of trastuzumab and scientific update. Semin Oncol, 28 (5 Suppl 16): 4~11
Behrendt N, Jensen O N, Engelholm L H, Mortz E, Mann M, Dano K. 2000. A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem, 275(3):1993~2002
Behrendt N, R?nne E, Dan? K. 1993. Binding of urokinase-type plasminogen activator to its cell-surface receptor is inhibited by low doses of suramin. J Biol Chem, 268(8): 5985~9
Bernstein E, Caudy A A, Hammond S M, et al. 2001. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 409(6818): 363～6
Blasi F, Carmeliet P. 2002. uPAR: a versatile signaling orchestrator. Net Rev Mol Cell Biol, 3(12): 932~43
Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signaling. Nature, 411(6835): 355~65
Bohuslav J, Horejsi V, Hansmann C, St?ckl J, Weidle U H, Majdic O, Bartke I, Knapp W, Stockinger H. 1995. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med, 181(4): 1381~90
Bonavaud S, Charrière-Bertrand C, Rey C, Leibovitch M P, Pedersen N, Frisdal E, Planus E, Blasi F, Gherardi R, Barlovatz-Meimon G. 1997. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion. J Cell Sci, 110(Pt9): 1083~9
BookmanM A, Darcy K M, Clarke-Pearson D, Boothby R A, Horowitz I R. 2003. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phaseⅡtrial of the Gynecologic OncologyGroup. J Clin Oncol, 21(2): 283 ~90
Boudewijn B M, Bos J L. 1995. Regulation of Ras mediated signalling: more than one way to skin a cat. Trends Biochem Sci, 20(1):18~22
Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmüller G, Pantel K. 2001. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I–III breast cancer patients. Cancer Res, 61(5):1890~5
Brennan P J, Kumagai T, Berezov A, Murali R, Greene M I. 2002. HER2/Neu: Mechanisms of dimerization/oligomerization. Oncogene, 21(2): 328
Burridge K, Fath R. 1989. Focal contacts: transmembrane links between the extracellular matrix and the cytoskeleton. Bioassays, 10(4): 104~8
Burstein H J, Kuter I, Campos S M, Gelman R S, Tribou L, Parker L M, Manola J, Younger J, Matulonis U, Bunnell C A, Partridge A H, Richardson P G, Clarke K, Shulman L N,Winer E P. 2001. Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol, 19(10): 2722~30
Busso N, Masur S K, Lazega D, Waxman S, Ossowski L. 1994. Induction of cell migration by urokinase binding its cellular receptor: possible mechanism for signal-transduction in human epithelial cells. J Cell Biol, 126(1): 259~70
Cai H, Erhardt P, Troppmair J, Diaz-Meco M T, Sithanandam G, Rapp U R, Moscat J, Cooper G M. 1993. Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal-transduction. Mol Cell Biol, 13(12): 7645~51
Cantero D, Friess H, Deflorin J, Zimmermann A, Bründler M A, Riesle E, Korc M, Büchler M W. 1997. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer, 75(3): 38~95
Chambers S K, Gertz R E Jr, Ivins C M, Kaoinski B M. 1995. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer, 75(7): 16272~33
Chapman H A. 1997. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol, 9(5): 714~724
Chardin P, Cussac D, Maignan S, Ducruix A. 1995. The Grb2 Adaptor. FEBS Lett, 369(1): 47~51
Chaurasia P, Aguirre-Ghiso J A, Liang O D, Gardsvoll H, Ploug M, Ossowski L. 2006. A region in urokinase plasminogen receptor domain III controlling a functional association withα5β1 integrin and tumor growth. J Biol Chem, 281(21): 14852~63
Chen F M, Hou M F, Wang J Y, Chen T C, Chen D C, Huang S Y, Chung Y S, Lin S R. 2004. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan. Cancer Lett, 207(1): 59~67
Chen H, Yu D, Chinnadurai G, Karunagaran D, Hung M C. 1997. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene, 14(16): 1965~71
Cho H S, Leahy D J. 2002. Structure of the extracellular region of HER3 reveals an interdomain tether. Science, 297(5585): 1330~3
Choudhury A , Charo J , Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R. 2004. Smallinterfering RNA (siRNA) inhibits the expression of the Her2Pneu gene , upregulates HLA classⅠand induces apoptosis of Her2Pneu positive tumor cell lines. Int J Cancer, 108(1): 71~7
Christensen L, Wiborg Simonsen A C, Heegaard C W, Moestrup S K, Andersen J A, Andreasen P A. 1996. Immunohistochemical localisation of urokinase-type plasminogen activator, type-1 plasminogen activator inhibitor, urokinase receptor and A2-macroglobulin in human breast carcinomas. Int J Cancer, 66(4): 441~52
Christianson T A, Doherty J K, Lin Y J, Ramsey E E, Holmes R, Keenan E J, Clinton G M. 1998. NH2-terminal truncated HER2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res, 58(22): 5123~9
Christodoulou C, Klouvas G, Pateli A, Pateli A, Mellou S, Sgouros J, Skarios D V. 2003. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. Anticancer Res, 23 (1B): 737~44
Ciambrone G J, McKeown-Longo P J. 1992. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem, 267(19): 13617~22
Coussens L, Yang-Feng T L, Liao Y C, Chen E, Gray A, McGrath J, Seeburg P H, Libermann T A, Schlessinger J, Francke U. 1985. Tyrosine kinase receptor with extensive homolgy to EGF receptor shares chromosomal location with neu oncogene. Science, 30(4730): 1132~9
Crowley C W, Cohen R L, Lucas B K, Liu G, Shuman M A, Levinson A D. 1993. Prevention of metastasis by inhibition of the urokinase receptor, Proc Natl Acad Sci USA, 90(11): 5021~5
Dear A E, Medcalf R L. 1998. The urokinase-type-plasminogen-activator receptor (CD87) is pleiotropic molecule. Eur J Biochem, 252(2): 185~93
Degryse B, Resnati M, Czekay R P, Loskutoff D J, Blasi F. 2005. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem. 280(26): 24791~803
Delebecq T J, Porte H, Zerimech F, Copin M C, Gouyer V, Dacquembronne E, Balduyck M, Wurtz A, Huet G. 2000. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin Cancer Res, 6(3): 1086~92
Deng G., Curriden S A, Wang S, Rosenberg S, Loskutoff D J. 1996. Is plasminogen activator inhibitor-1 the molecular switch that Governs urokinase receptor-mediated cell adhesion and release. J Cell Biol, 134(6): 1563~71
Dent P, Haser W, Haystead T A, Vincent L A, Roberts T M, Sturgill T W. 1992. Activation of mitogen-activated protein kinase kinase by v-raf in NIH 3T3 cells and in vitro. Science, 257(5075):1404~7
Ding Y B, Wu Z Y, Wang S, Fan P, Zha X M, Zheng W, Liu X A. 2004. Expression of tyrosine kinase Syk in breast cancer and their clinical Significance. Zhonghua Wai Ke Za Zhi, 42 (3): 137~9
Dubuisson L, Monvoisin A, Nielsen B S, Nielsen Le Bail B, Bioulac-Sage P, Rosenbaum J. 2000. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol, 190(2): 190~195
Dumler I, Kopmann A, Wagner K, Mayboroda O, Jerke U, Dietz R, Haller H, Gulba D C. 1999. Urokinase Induces Activation and Formation of Stat4 and Stat1-Stat2 Complexes in Human Vascular Smooth Muscle Cells. J Biol Chem, 274(34): 24059~65
Dumler I, Weis A, Mayboroda O, Maasch C, Jerke U, Haller H, Gulba D C. 1998. The Jak/Statpathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem, 273(1): 315~21
Ebner S, Lenz A, Reider D, Fritsch P, Schuler G, Romani N. 1998. Expression of maturation-/migration-related molecules on human dendritic cells from blood and skin. Immunobiology, 198(5): 568~87
Eccles S A. 2001. The role of c-ErbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia, 6(4): 393~406
Ellis V, Dan? K. 1993. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor mediated plasminogen activation. J Biol Chem, 268(7): 4806~13
Erpel T, Courtneidge S A. 1995. Src family protein kinases and cellular signal transduction pathways. Curr Opin Cell Biol, 7(2): 176~82
Estreicher A, Mühlhauser J, Carpentier J L, Orci L, Vassalli J D. 1990. The receptor for urokinase type plasminogen activator polarises expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol, 111(2): 783~92
Faltus T, Yuan J, Zimmer B, Kr?mer A, Loibl S, Kaufmann M, Strebhardt K. 2004. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia, 6(6): 786~95
Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. 1997. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J, 16(24): 7279~86
Fergenbaum J H, Garcia-Closas M, Hewitt S M, Lissowska J, Sakoda L C, Sherman M E. 2004. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev, 13(4): 667~72
Ferguson K M, Darling P J, Mohan M J, Macatee T L, Lemmon M A. 2000. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. Embo J, 19(17): 4632~43
Finkenzeller G, Weindel K, Zimmermann W, Westin G, MarméD. 2004. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis, 7(1): 59~68
Finkle D, Quan Z R, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong W L, Hollingshead P, Schwall R, Koeppen H, Erickson S. 2004. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res, 10(7): 2499~511
Fire A, Xu S, Montgomery M K, Kostas S A, Driver S E, Mello C C. 1998. Poetent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391(6669): 806~11
Fisher J L, Field C L, Zhou H, Harris T L, Henderson M A, Chong P F. 2000. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat, 61(1): 1~12
Folkman J, Browder T, Palmblad J. 2001. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost, 86(1): 23~33
Franco P, Iaccarino C, Chiaradonna F, Brandazza A, Iavarone C, Mastronicola R M, Nolli L M, Stoppelli P M. 1997. Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J Cell Biol, 137(3): 779~91
Franco P, Vocca I, Carriero M V, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli M P. 2006. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase andαvβ5 integrin. J Cell Sci, 119(Pt16): 3424~34
Fuchs I B, Loebbecke M, Buhler H, Stoltenburg-Didinger G, Heine B, Lichtenegger W, Schaller G.. 2002. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol, 20(19): 4130~3
Gancberg D, J?rvinen T, di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J, Larsimont D. 2002. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER2/NEU testing. Breast Cancer Res Treat, 74(2): 113~20
Gardsvoll H, Dano K, Ploug M. 1999. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J Biol Chem, 274(53): 37995~38003
Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, Grieco P, Peluse G, Stoppelli M P, Carriero M V. 2005. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem, 280(26): 25225~32
Garrett T P, McKern N M, Lou M, Elleman T C, Adams T E, Lovrecz G O, Zhu H J, Walker F, Frenkel M J, Hoyne P A, Jorissen R N, Nice E C, Burgess A W, Ward C W. 2002. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell, 110(6): 763~73
Gennar I R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Magalotti C, Gibelli N, Olivero B, Ballardini B, Da Prasa G, Zambelli A, Costa A. 2004. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Cancer Res, 10 (17): 5650～5
Ghannadan M, Baghestanian M, Wimazal F, Eisenmenger M, Latal D, Kargül G, Walchshofer S, Sillaber C, Lechner K, Valent P. 1998. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J Invest Dermatol, 111(4): 689~95
Ghosh S, Brown R, Jones J C, Ellerbroek S M, Stack M S. 2000. Urinarytype plasminogen activator (uPA) expression and uPA receptor localization are regulated byα3β1 integrin in oral keratinocytes. J Biol Chem, 275(31): 23869~76
Gillgrass A, Cardiff R D, Sharan N, Kannan S, Muller W J. 2003. Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene, 22(57): 9151~5
Goodson R J, Doyle M V, Kaufman S E, Rosenberg S. 1994. High affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA, 91(15): 7129~33
Gorodinsky A, Harris D A. 1995. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J Cell Biol, 129(3): 619~27
Goueli B S,Janknecht R. 2004. Upregulation of the Catalytic Telomerase Subunit by the TranscriptionFactor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol, 24(1): 25~35
Graus-Porta D, Beerli R R, Daly J M, Hynes N E. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J, 16(7):1647~55
Guilbert M, Ferland C, BosséM, Flammand N, Lavigne S, Laviolette M. 1999. 5-Oxo-6, 8, 11, 14-eicosatetraenoic acid induces important eosinophil transmigration through basement membrane components: comparison of normal and asthmatic eosinophils. Am J Respir Cell Mol Biol, 21(1): 97~104
Guy P M, Platko J V, Cantley L C, Cerione R A, Carraway K L 3rd. 1994. Insect cell-expressed pl80erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA, 91(17): 8132~6
Gyetko M R, Todd R F, Wilkinson C C, Sitrin R G. 1994. The urokinase receptor is required for human monocyte chemotaxis invitro. J Clin Invest, 93(4): 1380~7
Hansen S K, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle P A, Blasi F. 1992. A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J, 11(1): 205~13
Hébert C A, Baker J B. 1988. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: Colocalisation of cell surface urokinase with vinculin, J Cell Biol, 106(4): 1241~7
Hu X, Su F, Qin i, Jia W, Gong C, Yu F, Guo J, Song E. 2006. Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. Biochem Biophys Res Commun, 346(3): 778~85
Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg G M, Reeves K, Chen J, Robinson D, Li A, Lee F Y, Gottardis M M, Clark E, Helman L, Attar R M, Dongre A, Carboni J M. 2009. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res, 69(1): 161~70
Hutcheson I R, Knowlden J M, Madden T A, Barrow D, Gee J M, Wakeling A E, Nicholson R I. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway intamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat, 81(1): 81~93
Huttenlocher A, Sandborg R R, Horwitz A F. 1995. Adhesion in cell migration, Curr Opin Cell Biol, 7(5): 697~706
Hynes N E, Stern D F. 1994. The biology of p185/neu /HER2 and its role in cancer. Biochim Biophys Acta, 198(1): 165~184
Irigoyen J P, Mu?oz-Cánoves P, Montero L, Koziczak M, Nagamine Y. 1999. The plasminogen activator system: biology and regulation. Cell Mol Life Sci, 56(1-2): 104~32
Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain R K. 2002. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature, 416(6878): 279~80
Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton G M. 2003. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER2. Oncogene, 22(50): 8178~86
Jo M, Thomas K S, Takimoto S, Gaultier A, Hsieh E H, Lester R D, Gonias S L. 2007. Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene, 26(18): 2585~94
Jo M, Thomas K S, Wu L, Gonias S L. 2003. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem, 278(47): 46692~8
Jukkola A, Bloigu R, Soini Y, Savolainen E R, Holli K, Blanco G.. 2001. C-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer, 37(3): 347~54
Julio A, Aguirre-Ghiso. 2007. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer, 7(11): 834~46
Kanse S M, Kost C, Wilhelm O G, Andreasen P A, Preissner K T. 1996. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res, 224(2): 344~53
Kindzelskii A L, Laska Z O, Todd R F 3rd, Petty H R. 1996. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type3 (alpha M beta 2, CD11b/CD18) during neutrophil polarization. J Immunol, 156(1): 297~309
Kirchheimer J C, Remold H G. 1989. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol, 143(8): 2634~9
Kirchheimer J C, Wojta J, Christ G, Binder B R. 1987b. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J, 1(2): 125~8
Kirchheimer J C, Wojta J, Hienert G, Christ G, Heger M E, Pfluger H, Binder B R. 1987a. Effect of urokinase on the proliferation of primary cultures of human prostatic cells. Thromb Res, 48(3): 291~8
Kjoller L, Kanse S M, Kirkgaard T, Rodenburg K W, Ronne E, Goodman S L, Preissner K T, Ossowski L, Andreasen P A. 1997. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res, 232(2): 420~9
Klapper L N, Glathe S, Vaisman N, Hynes N E, Andrews G C, Sela M, Yarden Y. 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA, 96(9): 4995~5000
Klapper L N, Kirschbaum M H, Sela M, Yarden Y. 2000. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res, 77: 25~79.
Klos K S, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D, et al. 2003. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer, 98 (7) : 1377～85.
Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp U R. 1993. Protein kinase C alpha activates Raf-1 by direct phosphorylation. Nature, 364(6434):249~52
Konakova M, Hucho F, Schleuning W D. 1998. Downstream targets of uPA-uPAR-mediated signal transduction. Eur J Biochem, 253(2): 421~9
Kook Y H, Adamski J, Zelent A, Ossowski L. 1994. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J, 13(17): 3983~91
Koshelnick Y, Ehart M, Hufnagl P, Heinrich P C, Binder B R. 1997. Urokinase receptor is associated with the components of the JAK1/STAT1 signalling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumour cell line TCL-598. J Biol Chem, 272(45): 28563~7
Kugler M C, Wei Y, Chapman H A. 2003. Urokinase receptor and integrin interactions. Curr Pharm Des, 9(19): 1565~74
Kumar R,Yarmand-Bagheri R. 2001. The role of HER2 in angiogenesis. Semin Oncol, 28 (5 Suppl16): 27~32
Kunigal S, Lakka S S, Gondi C S, Estes N, Rao J S. 2007. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer, 121(10): 2307~16
Kunitomo K, Inoue S, Ichihara F, Kono K, Fujii H, Matsumoto Y, Ooi A. 2004. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. Hum Pathol, 35(3): 379~81
Kwaan H C, Wang J, Svoboda K, Declerck P J. 2000. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer, 82(10): 1702~8
La Rocca R V, Stein C A, Myers C E. 1990. Suramin: prototype of a new generation of antitumour compounds. Cancer Cells, 2(4): 106~15
L'Allemain G. 2003. HER-ErbB family of receptors and their ligands: mechanisms of activation,signals and deregulation in cancer. Bull Cancer, 90 Spec No: S179~85
Laughner E, Taghavi P, Chiles K, Mahon P C, Semenza G L. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 21(12): 3995~4004
Leevers S J, Paterson H F, Marshall C J. 1994. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature, 369(6479): 411~414
Li S, Couet J, Lisanti M P. 1996a. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem, 271(46): 29182~190
Li S, Okamoto T, Chun M, Sargiacomo M, Casanova J E, Hansen S H, Nishimoto I, Lisanti M P. 1995. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem, 270(26):15693~701
Li Y M, Pan Y, Wei Y, Cheng X, Zhou B P, Tan M, Zhou X, Xia W, Hortobagyi G N, Yu D, Hung M C. 2004. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 6(5): 459~69
Liu D, Aguirre-Ghiso J, Estrada Y, Ossowski L. 2002. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1(5): 445~57
Lu H, Mabilat C, Yeh P, Guitton J D, Li H, Pouchelet M, Shoevaert D, Legrand Y, Soria J, Soria C. 1996. Blockage of urokinase receptor reduces in vitro the motility and deformability of endothelial cells. FEBS Lett, 380(1-2): 21~4
Lutz V, Reuning U, Krüger A, Luther T, Pildner von steinberg S, Graeff H, Schmitt M, Wilhelm O G, Magdolen V. 2001. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem, 382 (5):7 89~Shakuntala
Mandal M, Vadlamudi R, Nguyen D, Wang R A, Costa L, Bagheri-Yarmand R, Mendelsohn J, Kumar R. 2001. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem, 276(13): 9699~704
Marmor M D, Skaria K B, Yarden Y. 2004. Signal transduction and oncogenesis by ErbB/HERreceptors. Int J Radiat Oncol Biol Phys, 58(3): 903~13
Mazar A P, Henkin J, Goldfarb R H. 1999. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis, 3(1): 15~32
Mazzieri R, Blasi F. 2005. The urokinase receptor and the regulation of cell proliferation. Thromb Haemost, 93(4): 641~6
Medema R H, Bos J L. 1993. The role of p21 ras in receptor tyrosine kinase signaling. Crit Rev Oncog, 4(6): 615~61
Meier R, Hemmings B A. 1999. Regulation of protein kinase B. J Recept Signal Transduct Res,19(1-4): 121~8
Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. 2001. Castiglioni F, et al. HER2 as a prognostic factor in breast cancer. Oncology, 61 Suppl 2: 67~72
Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW ., Lane N, Wang J, Uhr J. 2006. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA, 103(46): 17361~5
Miles D W, Harris W H, Gillett C E, Smith P, Barnes D M. 1999. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer, 84(4): 354~9
Mitteldorf C A, Leite K R, Meirelles M I, Gattas G J, Camara-Lopes L H. 2004. Overexpression of HER2/neu oncoprotein in cytologic specimens. Acta Cytol, 48(2): 199~206
Montuori N, Visconte V, Rossi G, Ragno P. 2005. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules. Thromb Haemost, 93(2): 192~8
Mousavi S A, Sato M, Sporst?l M, Smedsr?d B, Berg T, Kojima N, Senoo H. 2005. Uptake of denatured collagen into hepatic stellate cells: evidence for the involvement of urokinase plasminogen activator receptor-associated protein/Endo180. Biochem J, 387(Pt1): 39~46
Nagamine Y, Medcalf RL, Mu?oz-Cánoves P. 2005. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost, 93(4): 661~75
Napoli C, Lemieux C, Jorgensen R. 1990. Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell, 2(4): 279~289
Nguyen D H, Catling A D, Webb D J, Sankovic M, Walker L A, Somlyo A V, Weber M J, Gonias S L. 1999. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol, 146(1):149~64
Nguyen D H, Webb D J, Catling A D, Song Q, Dhakephalkar A, Weber M J, Ravichandran K S, Gonias S L. 2000. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem, 275(25): 19382~8
Nip J, Rabbani S A, Shibata H R, Brodt P. 1995. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest, 95(5): 2096~103
Noda-Heiny H, Daugherty A, Sobel B E. 1995. Augmented Urokinase Receptor Expression inatheroma. Arterioscler ThrombVase Biol, 15(1): 37~43
Nusrat A R, Chapman H A J. 1991. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest, 87(3): 1091~7
Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JvH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. 2002. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110(6): 775~87
Olayioye M A, Neve R M, Lane H A, Hynes N E. 2000. The ErbB signaling network: Receptor heterodimerization in development and cancer. Embo J, 19(13): 3159~67
Ossowski L, Aguirre-Ghiso J A. 2000. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol, 12(5): 613~20
Pannell R, Gurewich V. 1987. Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood, 69(1): 22~6
Pegram M D, Finn R S, Arzoo K, Beryt M, Pietras R J, Slamon D J. 1997. The effect of HER-2 /neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15(5): 537~47
Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, Pelicci P G. 1992. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell, 70(1): 93~104
Penault-Llorca F. 2003. Epidermal growth factor receptors: status evaluation methods and tumor expression. Bull Cancer, 90 Spec No: S186~91
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin B J, Sela M, Yarden Y. 1996. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J, 15(10): 2452~67
Plesner T, Ralfkiaer E, Wittrup M, Johnsen H, Pyke C, Pedersen T L, Hansen N E, Dan? K. 1994. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol, 102(6): 835~41
Ploug M, G ?rdsvoll H, J?rgensen T J, L?nborg Hansen L, Dan? K. 2002. Structural analysis of the interaction between urokinasetype plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy. Biochem Soc Trans, 30 (2): 177~83
Ploug M, R?nne E, Behrendt N, Jensen A L, Blasi F, Dan? K. 1991. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem, 266(3): 1926~33
Pluskota E, Soloviev D A, Bdeir K, Cines D B, Plow E F. 2004. IntegrinαMβ2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem, 279(17): 18063~72
P?ll?nen J, Hedman K, Nielsen L S, Dan? K, Vaheri A. 1988. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol, 106(1): 87~95
P?ll?nen J, Saksela O, Salonen E M, Andreasen P, Nielsen L, Dan? K, Vaheri A. 1987. Distinct localisations of urokinase-type plasminogen activator and its type1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol, 104(4): 1085~96
Prenzel N, Fischer O M, Streit S, Hart S, Ullrichet A. 2001. The epidermal growth factor receptorfamily as a central element for cellular signal transduction and diversification. Endocr Relat Cancer, 8(1): 11~31
Qi C, Li D J. 1999. Thermometric analysis of intra-cavitary hyperthermia for esophageal cancer. Int J Hyperthermia, 15(5): 399~407
Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, Del-Rosso M. 1995. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res, 55(1): 90~95
Rabbani S A, Gladu J. 2002. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res, 62(8): 2390~7
Reinartz J, Sch?fer B, Batrla R, Klein C E, Kramer M D. 1995. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res, 220(2): 274~82
Resnati M, Gutinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. 1996. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J, 15(7): 1572~82
Resnati M, Pallavicini I, Wang J M, Oppenheim J, Serhan C, Romano M, Blasi F. 2002. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA, 99(3): 1359~64
Romer J, Nielsen B S, Ploug M. 2004. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des, 10(19): 2359~76
Ross J S, Fletcher J A. 1998. The HER2 /neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells, 16 (6): 413~28
Ryo A, Liou Y C, Wulf G, Nakamura M, Lee S W, Lu K P. 2002. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol, 22(15): 5281~95
Samanta A, LeVea C M, Dougall W C, Qian X, Greene M I. 1994. Ligand and p185/neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci USA, 1994, 91(5): 1711~5
Sargiacomo M, Sudol M, Tang Z, Lisanti M P. 1993. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol, 122(4): 789~807
Sato S, Kopitz C, Schmalix W A, Schmalix W A, Muehlenweg B, Kessler H, Schmitt M, Krüger A, Magdolen V. 2002. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor interaction: effect on tumor growth and spread. FEBS Lett, 528 (1-3): 212~6
Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell, 103(2): 211~25
Schlessinger J. 2002. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell, 110(6): 669~72
Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, J?nicke F, H?fler H, Graeff H. 1995. Primary tumour and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res, 55(18): 3958~63
Schneeweiss A, Katretchko J, Sinn H P, Unnebrink K, Rudlowski C, Geberth M, Beldermann F, Bastert G, Strittmatter H J. 2004. Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs, 15(2): 127~35
Segatto O, King C R, Pierce J H, DiFiore P P, Aaronson S A. 1988. Different structural alterationsupregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Bio1, 8(12): 5570~4
Shakuntala Kondraganti, Christopher S Gondi, Ian McCutcheon, Dzung H Dinh, Meena Gujrati, Jasti S Rao, William C Olivero. 2006. RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Onco, 28(6): 1353~60
Sharp P A. 2001. RNA interference.Genes Dev, 15(5): 485～90
Shetty S, Rao G N, Cines D B, Bdeir K. 2006. Urokinase induces activation of STAT3 in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 291(4): L772~80
Shi Z, Stack M S. 2007. Urinary-type plasminogen activator (uPA) and its receptor (u PAR) in squamous cell carcinoma of the oral cavity. Biochen J, 407(20): 153~9
Shih C, Padhy L C, Murray M, Weinberg R A. 1981.Transforming genes of carcimomas and neuroblastomas introduced into mouse fiboblasts. Nature, 290(5803): 261~264
Siddiqa A, Long L M, Li L, Marciniak R A, Kazhdan I. 2008. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer, 8:129
Sier C F, Quax P H, Vloedgraven H J, Verheijen J H, Griffion G., Ganesh S, Lamers C B, Verspaget H W. 1993. Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastasis. Invasion Metastasis, 13(6): 277~88
Sier C F, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Feigerio L, Ferrari A, Dan?K, Brünner N, Blasi F. 1998. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res, 58(9): 1843~9
Simon D I, Wei Y, Zhang L, Rao N K, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman H A. 2000. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem, 275(14): 10228~34
Sitrin R G., Todd R F 3rd, Albrecht E, Gyetko M R. 1996. The urokinase receptor (CD 87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest, 97(8): 1942~51
Slamon D J, Clark G M, Wong S G., Ullirich A, McGuire W L. 1987. Human breast cancer: correlation of relapse and survival with amplification of theHER-2/neu oncogene. Science, 235(4785): 177~82
Soff G A, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwaan H C. 1995. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest, 96(6): 2593~600
Solit D B, Scher H I, Rosen N. 2003. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol, 30(5): 709~16
Soltoff S P, Cantley L C. 1996. p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. J Biol Chem, 271(1): 563~7
Srivastava M, Bubendorf L, Raffeld M, Bucher C, Torhorst J, Sauter G, Olsen C, Kallioniemi O P, Eidelman O, Pollard H B. 2004. Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. Clin Cancer Res, 10(7): 2344~50
Stahl A, Mueller B M. 1994. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res, 54(11): 3066~71
Stefansson S, Lawrence D A. 1996. The serpin PAI-1 inhibits cell migration by blocking integrin alphaV beta 3 binding to vitronectin. Nature, 383(6599): 441~3
Strauss B. 2000. Best hope or last hope: access to phase III clinical trials of HER2/neu for advanced stage breast cancer patients. J Adv Nurs, 31(2):259~66
Subramanian R, Gondi C S, Lakka S S, Jutla A, Rao J S. 2006. siRNA-mediated Simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol, 28(4): 831~9
Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.2007. Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer. Kobe J Med Sci, 53(5): 177~87
Tan M, Li P, Sun M, Yin G, Yu D. 2006. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene, 25(23): 3286~95
Tiseo M, Loprevite M, Ardizzoni A. 2004. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents, 4(2): 139~48
Tsai S W, Sun Y, Williams L E, Raubitschek A A, Wu A M, Shively J E. 2000. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem, 11(3): 327~34
Turken O, Kunter E, Cermik H, Isitmangil T, Kandemir G, Yaylaci M, Ozturk A. 2003. Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC). Neoplasma, 2003; 50(4): 257~61
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin B J, Yarden Y. 1996. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol, 16(10): 5276~87
Ueno N T, Yu D, Hung M C. 1997. Cheimosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 15(8): 953~60
Untch M, Ditsch N , Hermelink K. 2003. Immuno therapy: new op tions in breast cancer treatment. Expert Rev Anticancer Ther, 3(3): 403~8
Waltz D A, Chapman H A. 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem, 269(20): 14746~50
Waltz D A, Sailor L Z, Chapman H A. 1993. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest, 91(4): 1541~52
Wang N, Planus E, Pouchelet M, Fredberg J J, Barlovatz-Meimon G. 1995b. Urokinase receptor mediated mechanical force transfer across the cell surface. Am J Physiol, 268(4Pt1): 1062~6
Wang S C, Lien H C, Xia W, Chen I F, Lo H W, Wang Z, Ali-Seyed M, Lee D F, Bartholomeusz G, Ou-Yang F, Giri D K, Hung M C. 2004. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell, 6(3): 251~61
Wang X Q, Sun P, Paller A S. 2005. Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uAP receptor/αβintegrin/epidermalgrowth factor receptor interactions. J Invest Dermatol, 124(4): 839~48
Wang Y, Jones C J, Dang J J, Liang X, Olsen J E, Doe W F. 1994. Human urokinase receptor expression is inhibited by amiloride and induced by tumour necrosis factor and phorbol ester in colon cancer cells. FEBS Lett, 353(2): 138~42
Wang Y. 2001. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res Rev, 21(2): 146~70
Wei Y, Eble J A, Wang Z, Kreidberg J A, Chapman H A. 2001. Urokinase receptors promoteβ1 integrin function through interactions with integrinα3β1. Mol Biol Cell, 12(10): 2975~86
Wei Y, Lukashev M, Simon D I, Bodary S C, Rosenberg S, Doyle M V, Chapman H A. 1996. Regulation of integrin function by the urokinase receptor. Science, 273(5281):1551~5
Wei Y, Waltz D A, Rao N, Drummond R J, Rosenberg S, Chapman H A. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem, 69(51): 32380~8
Wells A and Marti U. 2002. Signalling shortcuts: Cell-surface receptors in the nucleus. Nat Rev Mol Cell Biol, 3(9): 697~702
Winters Z E, Leek R D, Bradburn M J, Norbury C J, Harris A L. 2003. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res, 5(6): R242~9
Xing R H, Rabbani S A. 1996. Overexpression of urokinase receptor in breast cancer cells results in increased tumour invasion, growth and metastasis. Int J Cancer, 67(3): 423~9
Xue W, Mizukami I, Todd R F 3rd, Petty H R. 1997. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res, 57(9):1682~9
Yang G, Cai K Q, Thompson-Lanza J A, Bast R C Jr, Liu J. 2004. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem, 279(6): 4339~45
Yarden Y. 2001. Biology of HER2 and its importance in breast cancer. Oncology, 61 Suppl 2: 1~13.
Yebra M, Goretzki L, Pfeifer M, Mueller B M. 1999. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res, 250(1): 231~40
Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung M C. 1995. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene, 11(7): 1383~8
Yu D, Suen T C, Yan D H, Chang L S, Hung M C. 1990. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA, 87(12): 4499~503.
Zhang F, Strand A, Robbins D, Cobb M H, Goldsmith E J. 1994. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature, 367(6465): 704~11
Zhang F, Tom C C, Kugler M C, Ching T T, Kreidberg J ., Wei Y, Chapman H A. 2003. Distinct ligand binding sites in integrinα3β1 regulate matrix adhesion and cell-cell contact. J Cell Biol, 163(1): 177~188
Allgayer H, Babic R, Gruetzner K U, Tarabichi A, Schildberg F W, Heiss M M. 2000. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol, 18(11): 2201~9
Amin D N, Perkins A S, Stern D F. 2004. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene, 23(7): 1428~38
Andreasen P A, Egelund R, Petersen H H. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci, 57 (1): 25~40
Anichini E, Zamperini A, Chevanne M, Caldini R, Pucci M, Fibbi G., Del Rosso M. 1997. Interaction of urokinase-type plasminogen activator with its receptor rapidly induces activation of glucose transporters. Biochemistry, 36(11): 3076~83
Azria D, Larbouret C, Robert B, Culine S, Ychou M, Verrelle P, Dubois JB, Pèlegrin A. 2003. Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials. Bull Cancer, 90 Spec No: S202~12
Baker E A, Bergin FG, Leaper D J. 2000. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol, 53: 307~12
Baselga J, Albanell J, Molina M A, Arribas J. 2001. Mechanism of action of trastuzumab and scientific update. Semin Oncol, 28 (5 Suppl 16): 4~11
Behrendt N, Jensen O N, Engelholm L H, Mortz E, Mann M, Dano K. 2000. A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem, 275(3):1993~2002
Behrendt N, R?nne E, Dan? K. 1993. Binding of urokinase-type plasminogen activator to its cell-surface receptor is inhibited by low doses of suramin. J Biol Chem, 268(8): 5985~9
Bernstein E, Caudy A A, Hammond S M, et al. 2001. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 409(6818): 363～6
Blasi F, Carmeliet P. 2002. uPAR: a versatile signaling orchestrator. Net Rev Mol Cell Biol, 3(12): 932~43
Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signaling. Nature, 411(6835): 355~65
Bohuslav J, Horejsi V, Hansmann C, St?ckl J, Weidle U H, Majdic O, Bartke I, Knapp W, Stockinger H. 1995. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med, 181(4): 1381~90
Bonavaud S, Charrière-Bertrand C, Rey C, Leibovitch M P, Pedersen N, Frisdal E, Planus E, Blasi F, Gherardi R, Barlovatz-Meimon G. 1997. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion. J Cell Sci, 110(Pt9): 1083~9
BookmanM A, Darcy K M, Clarke-Pearson D, Boothby R A, Horowitz I R. 2003. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phaseⅡtrial of the Gynecologic OncologyGroup. J Clin Oncol, 21(2): 283 ~90
Boudewijn B M, Bos J L. 1995. Regulation of Ras mediated signalling: more than one way to skin a cat. Trends Biochem Sci, 20(1):18~22
Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmüller G, Pantel K. 2001. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I–III breast cancer patients. Cancer Res, 61(5):1890~5
Brennan P J, Kumagai T, Berezov A, Murali R, Greene M I. 2002. HER2/Neu: Mechanisms of dimerization/oligomerization. Oncogene, 21(2): 328
Burridge K, Fath R. 1989. Focal contacts: transmembrane links between the extracellular matrix and the cytoskeleton. Bioassays, 10(4): 104~8
Burstein H J, Kuter I, Campos S M, Gelman R S, Tribou L, Parker L M, Manola J, Younger J, Matulonis U, Bunnell C A, Partridge A H, Richardson P G, Clarke K, Shulman L N,Winer E P. 2001. Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol, 19(10): 2722~30
Busso N, Masur S K, Lazega D, Waxman S, Ossowski L. 1994. Induction of cell migration by urokinase binding its cellular receptor: possible mechanism for signal-transduction in human epithelial cells. J Cell Biol, 126(1): 259~70
Cai H, Erhardt P, Troppmair J, Diaz-Meco M T, Sithanandam G, Rapp U R, Moscat J, Cooper G M. 1993. Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal-transduction. Mol Cell Biol, 13(12): 7645~51
Cantero D, Friess H, Deflorin J, Zimmermann A, Bründler M A, Riesle E, Korc M, Büchler M W. 1997. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer, 75(3): 38~95
Chambers S K, Gertz R E Jr, Ivins C M, Kaoinski B M. 1995. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer, 75(7): 16272~33
Chapman H A. 1997. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol, 9(5): 714~724
Chardin P, Cussac D, Maignan S, Ducruix A. 1995. The Grb2 Adaptor. FEBS Lett, 369(1): 47~51
Chaurasia P, Aguirre-Ghiso J A, Liang O D, Gardsvoll H, Ploug M, Ossowski L. 2006. A region in urokinase plasminogen receptor domain III controlling a functional association withα5β1 integrin and tumor growth. J Biol Chem, 281(21): 14852~63
Chen F M, Hou M F, Wang J Y, Chen T C, Chen D C, Huang S Y, Chung Y S, Lin S R. 2004. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan. Cancer Lett, 207(1): 59~67
Chen H, Yu D, Chinnadurai G, Karunagaran D, Hung M C. 1997. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene, 14(16): 1965~71
Cho H S, Leahy D J. 2002. Structure of the extracellular region of HER3 reveals an interdomain tether. Science, 297(5585): 1330~3
Choudhury A , Charo J , Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R. 2004. Smallinterfering RNA (siRNA) inhibits the expression of the Her2Pneu gene , upregulates HLA classⅠand induces apoptosis of Her2Pneu positive tumor cell lines. Int J Cancer, 108(1): 71~7
Christensen L, Wiborg Simonsen A C, Heegaard C W, Moestrup S K, Andersen J A, Andreasen P A. 1996. Immunohistochemical localisation of urokinase-type plasminogen activator, type-1 plasminogen activator inhibitor, urokinase receptor and A2-macroglobulin in human breast carcinomas. Int J Cancer, 66(4): 441~52
Christianson T A, Doherty J K, Lin Y J, Ramsey E E, Holmes R, Keenan E J, Clinton G M. 1998. NH2-terminal truncated HER2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res, 58(22): 5123~9
Christodoulou C, Klouvas G, Pateli A, Pateli A, Mellou S, Sgouros J, Skarios D V. 2003. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. Anticancer Res, 23 (1B): 737~44
Ciambrone G J, McKeown-Longo P J. 1992. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem, 267(19): 13617~22
Coussens L, Yang-Feng T L, Liao Y C, Chen E, Gray A, McGrath J, Seeburg P H, Libermann T A, Schlessinger J, Francke U. 1985. Tyrosine kinase receptor with extensive homolgy to EGF receptor shares chromosomal location with neu oncogene. Science, 30(4730): 1132~9
Crowley C W, Cohen R L, Lucas B K, Liu G, Shuman M A, Levinson A D. 1993. Prevention of metastasis by inhibition of the urokinase receptor, Proc Natl Acad Sci USA, 90(11): 5021~5
Dear A E, Medcalf R L. 1998. The urokinase-type-plasminogen-activator receptor (CD87) is pleiotropic molecule. Eur J Biochem, 252(2): 185~93
Degryse B, Resnati M, Czekay R P, Loskutoff D J, Blasi F. 2005. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem. 280(26): 24791~803
Delebecq T J, Porte H, Zerimech F, Copin M C, Gouyer V, Dacquembronne E, Balduyck M, Wurtz A, Huet G. 2000. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin Cancer Res, 6(3): 1086~92
Deng G., Curriden S A, Wang S, Rosenberg S, Loskutoff D J. 1996. Is plasminogen activator inhibitor-1 the molecular switch that Governs urokinase receptor-mediated cell adhesion and release. J Cell Biol, 134(6): 1563~71
Dent P, Haser W, Haystead T A, Vincent L A, Roberts T M, Sturgill T W. 1992. Activation of mitogen-activated protein kinase kinase by v-raf in NIH 3T3 cells and in vitro. Science, 257(5075):1404~7
Ding Y B, Wu Z Y, Wang S, Fan P, Zha X M, Zheng W, Liu X A. 2004. Expression of tyrosine kinase Syk in breast cancer and their clinical Significance. Zhonghua Wai Ke Za Zhi, 42 (3): 137~9
Dubuisson L, Monvoisin A, Nielsen B S, Nielsen Le Bail B, Bioulac-Sage P, Rosenbaum J. 2000. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol, 190(2): 190~195
Dumler I, Kopmann A, Wagner K, Mayboroda O, Jerke U, Dietz R, Haller H, Gulba D C. 1999. Urokinase Induces Activation and Formation of Stat4 and Stat1-Stat2 Complexes in Human Vascular Smooth Muscle Cells. J Biol Chem, 274(34): 24059~65
Dumler I, Weis A, Mayboroda O, Maasch C, Jerke U, Haller H, Gulba D C. 1998. The Jak/Statpathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem, 273(1): 315~21
Ebner S, Lenz A, Reider D, Fritsch P, Schuler G, Romani N. 1998. Expression of maturation-/migration-related molecules on human dendritic cells from blood and skin. Immunobiology, 198(5): 568~87
Eccles S A. 2001. The role of c-ErbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia, 6(4): 393~406
Ellis V, Dan? K. 1993. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor mediated plasminogen activation. J Biol Chem, 268(7): 4806~13
Erpel T, Courtneidge S A. 1995. Src family protein kinases and cellular signal transduction pathways. Curr Opin Cell Biol, 7(2): 176~82
Estreicher A, Mühlhauser J, Carpentier J L, Orci L, Vassalli J D. 1990. The receptor for urokinase type plasminogen activator polarises expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol, 111(2): 783~92
Faltus T, Yuan J, Zimmer B, Kr?mer A, Loibl S, Kaufmann M, Strebhardt K. 2004. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia, 6(6): 786~95
Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. 1997. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J, 16(24): 7279~86
Fergenbaum J H, Garcia-Closas M, Hewitt S M, Lissowska J, Sakoda L C, Sherman M E. 2004. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev, 13(4): 667~72
Ferguson K M, Darling P J, Mohan M J, Macatee T L, Lemmon M A. 2000. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. Embo J, 19(17): 4632~43
Finkenzeller G, Weindel K, Zimmermann W, Westin G, MarméD. 2004. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis, 7(1): 59~68
Finkle D, Quan Z R, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong W L, Hollingshead P, Schwall R, Koeppen H, Erickson S. 2004. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res, 10(7): 2499~511
Fire A, Xu S, Montgomery M K, Kostas S A, Driver S E, Mello C C. 1998. Poetent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391(6669): 806~11
Fisher J L, Field C L, Zhou H, Harris T L, Henderson M A, Chong P F. 2000. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat, 61(1): 1~12
Folkman J, Browder T, Palmblad J. 2001. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost, 86(1): 23~33
Franco P, Iaccarino C, Chiaradonna F, Brandazza A, Iavarone C, Mastronicola R M, Nolli L M, Stoppelli P M. 1997. Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J Cell Biol, 137(3): 779~91
Franco P, Vocca I, Carriero M V, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli M P. 2006. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase andαvβ5 integrin. J Cell Sci, 119(Pt16): 3424~34
Fuchs I B, Loebbecke M, Buhler H, Stoltenburg-Didinger G, Heine B, Lichtenegger W, Schaller G.. 2002. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol, 20(19): 4130~3
Gancberg D, J?rvinen T, di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J, Larsimont D. 2002. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER2/NEU testing. Breast Cancer Res Treat, 74(2): 113~20
Gardsvoll H, Dano K, Ploug M. 1999. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J Biol Chem, 274(53): 37995~38003
Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, Grieco P, Peluse G, Stoppelli M P, Carriero M V. 2005. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem, 280(26): 25225~32
Garrett T P, McKern N M, Lou M, Elleman T C, Adams T E, Lovrecz G O, Zhu H J, Walker F, Frenkel M J, Hoyne P A, Jorissen R N, Nice E C, Burgess A W, Ward C W. 2002. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell, 110(6): 763~73
Gennar I R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Magalotti C, Gibelli N, Olivero B, Ballardini B, Da Prasa G, Zambelli A, Costa A. 2004. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Cancer Res, 10 (17): 5650～5
Ghannadan M, Baghestanian M, Wimazal F, Eisenmenger M, Latal D, Kargül G, Walchshofer S, Sillaber C, Lechner K, Valent P. 1998. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J Invest Dermatol, 111(4): 689~95
Ghosh S, Brown R, Jones J C, Ellerbroek S M, Stack M S. 2000. Urinarytype plasminogen activator (uPA) expression and uPA receptor localization are regulated byα3β1 integrin in oral keratinocytes. J Biol Chem, 275(31): 23869~76
Gillgrass A, Cardiff R D, Sharan N, Kannan S, Muller W J. 2003. Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene, 22(57): 9151~5
Goodson R J, Doyle M V, Kaufman S E, Rosenberg S. 1994. High affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA, 91(15): 7129~33
Gorodinsky A, Harris D A. 1995. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J Cell Biol, 129(3): 619~27
Goueli B S,Janknecht R. 2004. Upregulation of the Catalytic Telomerase Subunit by the TranscriptionFactor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol, 24(1): 25~35
Graus-Porta D, Beerli R R, Daly J M, Hynes N E. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J, 16(7):1647~55
Guilbert M, Ferland C, BosséM, Flammand N, Lavigne S, Laviolette M. 1999. 5-Oxo-6, 8, 11, 14-eicosatetraenoic acid induces important eosinophil transmigration through basement membrane components: comparison of normal and asthmatic eosinophils. Am J Respir Cell Mol Biol, 21(1): 97~104
Guy P M, Platko J V, Cantley L C, Cerione R A, Carraway K L 3rd. 1994. Insect cell-expressed pl80erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA, 91(17): 8132~6
Gyetko M R, Todd R F, Wilkinson C C, Sitrin R G. 1994. The urokinase receptor is required for human monocyte chemotaxis invitro. J Clin Invest, 93(4): 1380~7
Hansen S K, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle P A, Blasi F. 1992. A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J, 11(1): 205~13
Hébert C A, Baker J B. 1988. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: Colocalisation of cell surface urokinase with vinculin, J Cell Biol, 106(4): 1241~7
Hu X, Su F, Qin i, Jia W, Gong C, Yu F, Guo J, Song E. 2006. Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. Biochem Biophys Res Commun, 346(3): 778~85
Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg G M, Reeves K, Chen J, Robinson D, Li A, Lee F Y, Gottardis M M, Clark E, Helman L, Attar R M, Dongre A, Carboni J M. 2009. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res, 69(1): 161~70
Hutcheson I R, Knowlden J M, Madden T A, Barrow D, Gee J M, Wakeling A E, Nicholson R I. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway intamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat, 81(1): 81~93
Huttenlocher A, Sandborg R R, Horwitz A F. 1995. Adhesion in cell migration, Curr Opin Cell Biol, 7(5): 697~706
Hynes N E, Stern D F. 1994. The biology of p185/neu /HER2 and its role in cancer. Biochim Biophys Acta, 198(1): 165~184
Irigoyen J P, Mu?oz-Cánoves P, Montero L, Koziczak M, Nagamine Y. 1999. The plasminogen activator system: biology and regulation. Cell Mol Life Sci, 56(1-2): 104~32
Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain R K. 2002. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature, 416(6878): 279~80
Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton G M. 2003. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER2. Oncogene, 22(50): 8178~86
Jo M, Thomas K S, Takimoto S, Gaultier A, Hsieh E H, Lester R D, Gonias S L. 2007. Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene, 26(18): 2585~94
Jo M, Thomas K S, Wu L, Gonias S L. 2003. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem, 278(47): 46692~8
Jukkola A, Bloigu R, Soini Y, Savolainen E R, Holli K, Blanco G.. 2001. C-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer, 37(3): 347~54
Julio A, Aguirre-Ghiso. 2007. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer, 7(11): 834~46
Kanse S M, Kost C, Wilhelm O G, Andreasen P A, Preissner K T. 1996. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res, 224(2): 344~53
Kindzelskii A L, Laska Z O, Todd R F 3rd, Petty H R. 1996. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type3 (alpha M beta 2, CD11b/CD18) during neutrophil polarization. J Immunol, 156(1): 297~309
Kirchheimer J C, Remold H G. 1989. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol, 143(8): 2634~9
Kirchheimer J C, Wojta J, Christ G, Binder B R. 1987b. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J, 1(2): 125~8
Kirchheimer J C, Wojta J, Hienert G, Christ G, Heger M E, Pfluger H, Binder B R. 1987a. Effect of urokinase on the proliferation of primary cultures of human prostatic cells. Thromb Res, 48(3): 291~8
Kjoller L, Kanse S M, Kirkgaard T, Rodenburg K W, Ronne E, Goodman S L, Preissner K T, Ossowski L, Andreasen P A. 1997. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res, 232(2): 420~9
Klapper L N, Glathe S, Vaisman N, Hynes N E, Andrews G C, Sela M, Yarden Y. 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA, 96(9): 4995~5000
Klapper L N, Kirschbaum M H, Sela M, Yarden Y. 2000. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res, 77: 25~79.
Klos K S, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D, et al. 2003. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer, 98 (7) : 1377～85.
Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp U R. 1993. Protein kinase C alpha activates Raf-1 by direct phosphorylation. Nature, 364(6434):249~52
Konakova M, Hucho F, Schleuning W D. 1998. Downstream targets of uPA-uPAR-mediated signal transduction. Eur J Biochem, 253(2): 421~9
Kook Y H, Adamski J, Zelent A, Ossowski L. 1994. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J, 13(17): 3983~91
Koshelnick Y, Ehart M, Hufnagl P, Heinrich P C, Binder B R. 1997. Urokinase receptor is associated with the components of the JAK1/STAT1 signalling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumour cell line TCL-598. J Biol Chem, 272(45): 28563~7
Kugler M C, Wei Y, Chapman H A. 2003. Urokinase receptor and integrin interactions. Curr Pharm Des, 9(19): 1565~74
Kumar R,Yarmand-Bagheri R. 2001. The role of HER2 in angiogenesis. Semin Oncol, 28 (5 Suppl16): 27~32
Kunigal S, Lakka S S, Gondi C S, Estes N, Rao J S. 2007. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer, 121(10): 2307~16
Kunitomo K, Inoue S, Ichihara F, Kono K, Fujii H, Matsumoto Y, Ooi A. 2004. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. Hum Pathol, 35(3): 379~81
Kwaan H C, Wang J, Svoboda K, Declerck P J. 2000. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer, 82(10): 1702~8
La Rocca R V, Stein C A, Myers C E. 1990. Suramin: prototype of a new generation of antitumour compounds. Cancer Cells, 2(4): 106~15
L'Allemain G. 2003. HER-ErbB family of receptors and their ligands: mechanisms of activation,signals and deregulation in cancer. Bull Cancer, 90 Spec No: S179~85
Laughner E, Taghavi P, Chiles K, Mahon P C, Semenza G L. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 21(12): 3995~4004
Leevers S J, Paterson H F, Marshall C J. 1994. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature, 369(6479): 411~414
Li S, Couet J, Lisanti M P. 1996a. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem, 271(46): 29182~190
Li S, Okamoto T, Chun M, Sargiacomo M, Casanova J E, Hansen S H, Nishimoto I, Lisanti M P. 1995. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem, 270(26):15693~701
Li Y M, Pan Y, Wei Y, Cheng X, Zhou B P, Tan M, Zhou X, Xia W, Hortobagyi G N, Yu D, Hung M C. 2004. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 6(5): 459~69
Liu D, Aguirre-Ghiso J, Estrada Y, Ossowski L. 2002. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1(5): 445~57
Lu H, Mabilat C, Yeh P, Guitton J D, Li H, Pouchelet M, Shoevaert D, Legrand Y, Soria J, Soria C. 1996. Blockage of urokinase receptor reduces in vitro the motility and deformability of endothelial cells. FEBS Lett, 380(1-2): 21~4
Lutz V, Reuning U, Krüger A, Luther T, Pildner von steinberg S, Graeff H, Schmitt M, Wilhelm O G, Magdolen V. 2001. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem, 382 (5):7 89~Shakuntala
Mandal M, Vadlamudi R, Nguyen D, Wang R A, Costa L, Bagheri-Yarmand R, Mendelsohn J, Kumar R. 2001. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem, 276(13): 9699~704
Marmor M D, Skaria K B, Yarden Y. 2004. Signal transduction and oncogenesis by ErbB/HERreceptors. Int J Radiat Oncol Biol Phys, 58(3): 903~13
Mazar A P, Henkin J, Goldfarb R H. 1999. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis, 3(1): 15~32
Mazzieri R, Blasi F. 2005. The urokinase receptor and the regulation of cell proliferation. Thromb Haemost, 93(4): 641~6
Medema R H, Bos J L. 1993. The role of p21 ras in receptor tyrosine kinase signaling. Crit Rev Oncog, 4(6): 615~61
Meier R, Hemmings B A. 1999. Regulation of protein kinase B. J Recept Signal Transduct Res,19(1-4): 121~8
Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. 2001. Castiglioni F, et al. HER2 as a prognostic factor in breast cancer. Oncology, 61 Suppl 2: 67~72
Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW ., Lane N, Wang J, Uhr J. 2006. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA, 103(46): 17361~5
Miles D W, Harris W H, Gillett C E, Smith P, Barnes D M. 1999. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer, 84(4): 354~9
Mitteldorf C A, Leite K R, Meirelles M I, Gattas G J, Camara-Lopes L H. 2004. Overexpression of HER2/neu oncoprotein in cytologic specimens. Acta Cytol, 48(2): 199~206
Montuori N, Visconte V, Rossi G, Ragno P. 2005. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules. Thromb Haemost, 93(2): 192~8
Mousavi S A, Sato M, Sporst?l M, Smedsr?d B, Berg T, Kojima N, Senoo H. 2005. Uptake of denatured collagen into hepatic stellate cells: evidence for the involvement of urokinase plasminogen activator receptor-associated protein/Endo180. Biochem J, 387(Pt1): 39~46
Nagamine Y, Medcalf RL, Mu?oz-Cánoves P. 2005. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost, 93(4): 661~75
Napoli C, Lemieux C, Jorgensen R. 1990. Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell, 2(4): 279~289
Nguyen D H, Catling A D, Webb D J, Sankovic M, Walker L A, Somlyo A V, Weber M J, Gonias S L. 1999. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol, 146(1):149~64
Nguyen D H, Webb D J, Catling A D, Song Q, Dhakephalkar A, Weber M J, Ravichandran K S, Gonias S L. 2000. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem, 275(25): 19382~8
Nip J, Rabbani S A, Shibata H R, Brodt P. 1995. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest, 95(5): 2096~103
Noda-Heiny H, Daugherty A, Sobel B E. 1995. Augmented Urokinase Receptor Expression inatheroma. Arterioscler ThrombVase Biol, 15(1): 37~43
Nusrat A R, Chapman H A J. 1991. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest, 87(3): 1091~7
Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JvH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. 2002. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110(6): 775~87
Olayioye M A, Neve R M, Lane H A, Hynes N E. 2000. The ErbB signaling network: Receptor heterodimerization in development and cancer. Embo J, 19(13): 3159~67
Ossowski L, Aguirre-Ghiso J A. 2000. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol, 12(5): 613~20
Pannell R, Gurewich V. 1987. Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood, 69(1): 22~6
Pegram M D, Finn R S, Arzoo K, Beryt M, Pietras R J, Slamon D J. 1997. The effect of HER-2 /neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15(5): 537~47
Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, Pelicci P G. 1992. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell, 70(1): 93~104
Penault-Llorca F. 2003. Epidermal growth factor receptors: status evaluation methods and tumor expression. Bull Cancer, 90 Spec No: S186~91
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin B J, Sela M, Yarden Y. 1996. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J, 15(10): 2452~67
Plesner T, Ralfkiaer E, Wittrup M, Johnsen H, Pyke C, Pedersen T L, Hansen N E, Dan? K. 1994. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol, 102(6): 835~41
Ploug M, G ?rdsvoll H, J?rgensen T J, L?nborg Hansen L, Dan? K. 2002. Structural analysis of the interaction between urokinasetype plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy. Biochem Soc Trans, 30 (2): 177~83
Ploug M, R?nne E, Behrendt N, Jensen A L, Blasi F, Dan? K. 1991. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem, 266(3): 1926~33
Pluskota E, Soloviev D A, Bdeir K, Cines D B, Plow E F. 2004. IntegrinαMβ2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem, 279(17): 18063~72
P?ll?nen J, Hedman K, Nielsen L S, Dan? K, Vaheri A. 1988. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol, 106(1): 87~95
P?ll?nen J, Saksela O, Salonen E M, Andreasen P, Nielsen L, Dan? K, Vaheri A. 1987. Distinct localisations of urokinase-type plasminogen activator and its type1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol, 104(4): 1085~96
Prenzel N, Fischer O M, Streit S, Hart S, Ullrichet A. 2001. The epidermal growth factor receptorfamily as a central element for cellular signal transduction and diversification. Endocr Relat Cancer, 8(1): 11~31
Qi C, Li D J. 1999. Thermometric analysis of intra-cavitary hyperthermia for esophageal cancer. Int J Hyperthermia, 15(5): 399~407
Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, Del-Rosso M. 1995. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res, 55(1): 90~95
Rabbani S A, Gladu J. 2002. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res, 62(8): 2390~7
Reinartz J, Sch?fer B, Batrla R, Klein C E, Kramer M D. 1995. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res, 220(2): 274~82
Resnati M, Gutinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. 1996. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J, 15(7): 1572~82
Resnati M, Pallavicini I, Wang J M, Oppenheim J, Serhan C, Romano M, Blasi F. 2002. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA, 99(3): 1359~64
Romer J, Nielsen B S, Ploug M. 2004. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des, 10(19): 2359~76
Ross J S, Fletcher J A. 1998. The HER2 /neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells, 16 (6): 413~28
Ryo A, Liou Y C, Wulf G, Nakamura M, Lee S W, Lu K P. 2002. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol, 22(15): 5281~95
Samanta A, LeVea C M, Dougall W C, Qian X, Greene M I. 1994. Ligand and p185/neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci USA, 1994, 91(5): 1711~5
Sargiacomo M, Sudol M, Tang Z, Lisanti M P. 1993. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol, 122(4): 789~807
Sato S, Kopitz C, Schmalix W A, Schmalix W A, Muehlenweg B, Kessler H, Schmitt M, Krüger A, Magdolen V. 2002. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor interaction: effect on tumor growth and spread. FEBS Lett, 528 (1-3): 212~6
Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell, 103(2): 211~25
Schlessinger J. 2002. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell, 110(6): 669~72
Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, J?nicke F, H?fler H, Graeff H. 1995. Primary tumour and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res, 55(18): 3958~63
Schneeweiss A, Katretchko J, Sinn H P, Unnebrink K, Rudlowski C, Geberth M, Beldermann F, Bastert G, Strittmatter H J. 2004. Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs, 15(2): 127~35
Segatto O, King C R, Pierce J H, DiFiore P P, Aaronson S A. 1988. Different structural alterationsupregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Bio1, 8(12): 5570~4
Shakuntala Kondraganti, Christopher S Gondi, Ian McCutcheon, Dzung H Dinh, Meena Gujrati, Jasti S Rao, William C Olivero. 2006. RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Onco, 28(6): 1353~60
Sharp P A. 2001. RNA interference.Genes Dev, 15(5): 485～90
Shetty S, Rao G N, Cines D B, Bdeir K. 2006. Urokinase induces activation of STAT3 in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol, 291(4): L772~80
Shi Z, Stack M S. 2007. Urinary-type plasminogen activator (uPA) and its receptor (u PAR) in squamous cell carcinoma of the oral cavity. Biochen J, 407(20): 153~9
Shih C, Padhy L C, Murray M, Weinberg R A. 1981.Transforming genes of carcimomas and neuroblastomas introduced into mouse fiboblasts. Nature, 290(5803): 261~264
Siddiqa A, Long L M, Li L, Marciniak R A, Kazhdan I. 2008. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer, 8:129
Sier C F, Quax P H, Vloedgraven H J, Verheijen J H, Griffion G., Ganesh S, Lamers C B, Verspaget H W. 1993. Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastasis. Invasion Metastasis, 13(6): 277~88
Sier C F, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Feigerio L, Ferrari A, Dan?K, Brünner N, Blasi F. 1998. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res, 58(9): 1843~9
Simon D I, Wei Y, Zhang L, Rao N K, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman H A. 2000. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem, 275(14): 10228~34
Sitrin R G., Todd R F 3rd, Albrecht E, Gyetko M R. 1996. The urokinase receptor (CD 87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest, 97(8): 1942~51
Slamon D J, Clark G M, Wong S G., Ullirich A, McGuire W L. 1987. Human breast cancer: correlation of relapse and survival with amplification of theHER-2/neu oncogene. Science, 235(4785): 177~82
Soff G A, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwaan H C. 1995. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest, 96(6): 2593~600
Solit D B, Scher H I, Rosen N. 2003. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol, 30(5): 709~16
Soltoff S P, Cantley L C. 1996. p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. J Biol Chem, 271(1): 563~7
Srivastava M, Bubendorf L, Raffeld M, Bucher C, Torhorst J, Sauter G, Olsen C, Kallioniemi O P, Eidelman O, Pollard H B. 2004. Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. Clin Cancer Res, 10(7): 2344~50
Stahl A, Mueller B M. 1994. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res, 54(11): 3066~71
Stefansson S, Lawrence D A. 1996. The serpin PAI-1 inhibits cell migration by blocking integrin alphaV beta 3 binding to vitronectin. Nature, 383(6599): 441~3
Strauss B. 2000. Best hope or last hope: access to phase III clinical trials of HER2/neu for advanced stage breast cancer patients. J Adv Nurs, 31(2):259~66
Subramanian R, Gondi C S, Lakka S S, Jutla A, Rao J S. 2006. siRNA-mediated Simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol, 28(4): 831~9
Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.2007. Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer. Kobe J Med Sci, 53(5): 177~87
Tan M, Li P, Sun M, Yin G, Yu D. 2006. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene, 25(23): 3286~95
Tiseo M, Loprevite M, Ardizzoni A. 2004. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents, 4(2): 139~48
Tsai S W, Sun Y, Williams L E, Raubitschek A A, Wu A M, Shively J E. 2000. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem, 11(3): 327~34
Turken O, Kunter E, Cermik H, Isitmangil T, Kandemir G, Yaylaci M, Ozturk A. 2003. Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC). Neoplasma, 2003; 50(4): 257~61
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin B J, Yarden Y. 1996. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol, 16(10): 5276~87
Ueno N T, Yu D, Hung M C. 1997. Cheimosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 15(8): 953~60
Untch M, Ditsch N , Hermelink K. 2003. Immuno therapy: new op tions in breast cancer treatment. Expert Rev Anticancer Ther, 3(3): 403~8
Waltz D A, Chapman H A. 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem, 269(20): 14746~50
Waltz D A, Sailor L Z, Chapman H A. 1993. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest, 91(4): 1541~52
Wang N, Planus E, Pouchelet M, Fredberg J J, Barlovatz-Meimon G. 1995b. Urokinase receptor mediated mechanical force transfer across the cell surface. Am J Physiol, 268(4Pt1): 1062~6
Wang S C, Lien H C, Xia W, Chen I F, Lo H W, Wang Z, Ali-Seyed M, Lee D F, Bartholomeusz G, Ou-Yang F, Giri D K, Hung M C. 2004. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell, 6(3): 251~61
Wang X Q, Sun P, Paller A S. 2005. Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uAP receptor/αβintegrin/epidermalgrowth factor receptor interactions. J Invest Dermatol, 124(4): 839~48
Wang Y, Jones C J, Dang J J, Liang X, Olsen J E, Doe W F. 1994. Human urokinase receptor expression is inhibited by amiloride and induced by tumour necrosis factor and phorbol ester in colon cancer cells. FEBS Lett, 353(2): 138~42
Wang Y. 2001. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res Rev, 21(2): 146~70
Wei Y, Eble J A, Wang Z, Kreidberg J A, Chapman H A. 2001. Urokinase receptors promoteβ1 integrin function through interactions with integrinα3β1. Mol Biol Cell, 12(10): 2975~86
Wei Y, Lukashev M, Simon D I, Bodary S C, Rosenberg S, Doyle M V, Chapman H A. 1996. Regulation of integrin function by the urokinase receptor. Science, 273(5281):1551~5
Wei Y, Waltz D A, Rao N, Drummond R J, Rosenberg S, Chapman H A. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem, 69(51): 32380~8
Wells A and Marti U. 2002. Signalling shortcuts: Cell-surface receptors in the nucleus. Nat Rev Mol Cell Biol, 3(9): 697~702
Winters Z E, Leek R D, Bradburn M J, Norbury C J, Harris A L. 2003. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res, 5(6): R242~9
Xing R H, Rabbani S A. 1996. Overexpression of urokinase receptor in breast cancer cells results in increased tumour invasion, growth and metastasis. Int J Cancer, 67(3): 423~9
Xue W, Mizukami I, Todd R F 3rd, Petty H R. 1997. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res, 57(9):1682~9
Yang G, Cai K Q, Thompson-Lanza J A, Bast R C Jr, Liu J. 2004. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem, 279(6): 4339~45
Yarden Y. 2001. Biology of HER2 and its importance in breast cancer. Oncology, 61 Suppl 2: 1~13.
Yebra M, Goretzki L, Pfeifer M, Mueller B M. 1999. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res, 250(1): 231~40
Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung M C. 1995. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene, 11(7): 1383~8
Yu D, Suen T C, Yan D H, Chang L S, Hung M C. 1990. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA, 87(12): 4499~503.
Zhang F, Strand A, Robbins D, Cobb M H, Goldsmith E J. 1994. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature, 367(6465): 704~11
Zhang F, Tom C C, Kugler M C, Ching T T, Kreidberg J ., Wei Y, Chapman H A. 2003. Distinct ligand binding sites in integrinα3β1 regulate matrix adhesion and cell-cell contact. J Cell Biol, 163(1): 177~188